Journal article
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial
Abstract
BACKGROUND: The combination of three blood-pressure-lowering drugs at low doses, with a statin, aspirin, and folic acid (the polypill), could reduce cardiovascular events by more than 80% in healthy individuals. We examined the effect of the Polycap on blood pressure, lipids, heart rate, and urinary thromboxane B2, and assessed its tolerability.
METHODS: In a double-blind trial in 50 centres in India, 2053 individuals without cardiovascular …
Authors
Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
Journal
The Lancet, Vol. 373, No. 9672, pp. 1341–1351
Publisher
Elsevier
Publication Date
April 2009
DOI
10.1016/s0140-6736(09)60611-5
ISSN
0140-6736
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Adrenergic beta-AntagonistsAgedAged, 80 and overAnalysis of VarianceAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAspirinAtenololCardiovascular DiseasesDouble-Blind MethodDrug CombinationsDrug Therapy, CombinationHumansHydrochlorothiazideHydroxymethylglutaryl-CoA Reductase InhibitorsIndiaMiddle AgedPlatelet Aggregation InhibitorsRamiprilRisk FactorsRisk Reduction BehaviorSimvastatinTreatment Outcome